Samsung Biologics (207940) financial statements
+750.5%since 2018
- FY2025 revenue
- ₩4.6T▲ +30.3%
- FY2025 net income
- ₩1.8T▲ +64.7%
- FY2025 free cash flow
- ₩856.1B▲ +140.7%
Samsung Biologics income statement
| KRW millions | FY2025 | FY2024 | FY2023 |
|---|---|---|---|
| Period ended | 31 Dec 2025 | 31 Dec 2024 | 31 Dec 2023 |
| Revenue | 4,556,972 | 3,497,146 | 2,938,756 |
| Gross profit | 2,516,640 | 1,711,185 | 1,490,104 |
| Operating income | 2,069,221 | 1,321,366 | 1,205,546 |
| Pretax income | 2,118,631 | 1,384,869 | 1,231,334 |
| Net income | 1,784,352 | 1,083,316 | 857,691 |
| Diluted earnings per share | n/a | 15,221.00 | 12,051.00 |
Samsung Biologics balance sheet
| KRW millions | FY2025 | FY2024 | FY2023 |
|---|---|---|---|
| Period ended | 31 Dec 2025 | 31 Dec 2024 | 31 Dec 2023 |
| Cash and cash equivalents | 148,851 | 391,222 | 367,937 |
| Total assets | 11,060,742 | 17,336,296 | 16,046,197 |
| Total liabilities | 3,609,631 | 6,431,620 | 6,215,705 |
| Total equity | 7,451,111 | 10,904,676 | 9,830,492 |
| Long-term debt | 599,012 | 1,012,757 | 239,783 |
Samsung Biologics cash flow statement
| KRW millions | FY2025 | FY2024 | FY2023 |
|---|---|---|---|
| Period ended | 31 Dec 2025 | 31 Dec 2024 | 31 Dec 2023 |
| Operating cash flow | 2,247,807 | 1,659,255 | 1,666,229 |
| Capital expenditure | -1,391,741 | -1,303,573 | -995,071 |
| Free cash flow (derived) | 856,067 | 355,682 | 671,158 |
Quarterly highlights
| KRW millions | Q3 FY2026 | Q2 FY2026 | Q1 FY2026 | Q4 FY2025 |
|---|---|---|---|---|
| Period ended | 30 Sep 2026 | 30 Jun 2026 | 31 Mar 2026 | 31 Dec 2025 |
| Revenue (derived) | 1,490,325 | 1,320,911 | 1,257,119 | 308,573 |
| Operating income (derived) | 640,091 | 586,444 | 580,753 | 378,085 |
| Net income (derived) | 391,102 | 430,654 | 469,245 | 509,953 |
| Operating cash flow (derived) | 408,784 | 624,805 | 767,683 | 422,151 |
| Total assets | 12,670,151 | 12,652,621 | 11,995,000 | 11,060,742 |
Samsung Biologics major shareholders
| Holder | Share of class | Shares | Filed |
|---|---|---|---|
| 삼성물산 | 74.3% | 34,402,953 | 6 November 2025 |
| 국민연금공단 | 6.9% | 3,186,122 | 30 July 2026 |
Samsung Biologics DART filings
| Filed | Form | Type |
|---|---|---|
| 15 November 2026 | Quarterly Report | Quarterly report |
| 27 August 2026 | Major Matters Report | Current report |
| 13 August 2026 | Semiannual Report | Half-year report |
| 19 July 2026 | Major Matters Report | Current report |
| 14 May 2026 | Quarterly Report | Quarterly report |
| 11 March 2026 | Business Report | Annual report |
| 13 November 2025 | Quarterly Report | Quarterly report |
| 13 August 2025 | Semiannual Report | Half-year report |
Common questions
What was Samsung Biologics' revenue in fiscal 2025?
Samsung Biologics reported ₩4.6 trillion in revenue for fiscal 2025, the year ended 31 December 2025, up 30.3% from fiscal 2024.
What was Samsung Biologics' net income in fiscal 2025?
Samsung Biologics reported net income of ₩1.8 trillion for fiscal 2025, the year ended 31 December 2025, up 64.7% from fiscal 2024.
What was Samsung Biologics' free cash flow in fiscal 2025?
Samsung Biologics had ₩856.1 billion in free cash flow in fiscal 2025. Operating cash flow was ₩2.2 trillion and capital expenditure was ₩1.4 trillion.
What were Samsung Biologics' total assets at the end of fiscal 2025?
Samsung Biologics reported total assets of ₩11.1 trillion at the end of fiscal 2025, the year ended 31 December 2025.
How much Samsung Biologics history do I get?
Every account gets the full history, annual and quarterly, with first reported values and as of dates.
Start with a free key
Free $10 credits every month, no card.Free $10 credits a month, no card.